Refractory infantile high‐grade glioma containing TRK‐fusion responds to larotrectinib
- 5 January 2021
- journal article
- letter
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (5), e28868
- https://doi.org/10.1002/pbc.28868
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsThe Lancet Oncology, 2020
- Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomasNature Communications, 2019
- Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade gliomaBritish Journal of Cancer, 2018
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 studyThe Lancet Oncology, 2018
- High-grade glioma in very young children: a rare and particular patient populationOncotarget, 2017
- Genetic Analysis of Diffuse High‐Grade Astrocytomas in Infancy Defines a Novel Molecular EntityBrain Pathology, 2014
- The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade gliomaNature Genetics, 2014